Clinical Trial: Magnetic Stimulation Therapy for Treating Vascular Depression

This study is currently recruiting patients.

Sponsored by: National Institute of Mental Health (NIMH)
Information provided by: National Institute of Mental Health (NIMH)


The purpose of this study is to examine the effectiveness of repetitive transcranial magnetic stimulation (rTMS) in treating vascular depression.

Condition Treatment or Intervention Phase
Depressive Disorder
 Procedure: Repetitive Transcranial Magnetic Stimulation
 Drug: Citalopram
Phase III

MedlinePlus related topics:  Depression;   Mental Health

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study

Official Title: Vascular Depression and Magnetic Stimulation Therapy

Further Study Details: 

Expected Total Enrollment:  132

Study start: September 2001

Vascular depression is a condition that typically affects the elderly and is associated with small vascular lesions. It is more resistant to treatment and has a poorer outcome than nonvascular depression. By altering excitability in the cortical area of the brain, rTMS may be an effective treatment neuropsychiatric conditions, particularly depression.

Participants in this study will be randomly assigned to 15 treatments of either rTMS or sham rTMS for 3 weeks. Following treatment, participants will receive citalopram for 9 weeks. Response rates to treatment; relapse rates; the size, number, and location of the vascular lesions; and the amount of regional brain atrophy will be measured. Improvements in activities of daily living, quality of life, and cognitive function will also be also measured.


Ages Eligible for Study:  51 Years   -   89 Years,  Genders Eligible for Study:  Both


Inclusion Criteria:

  • DSM-IV diagnosis of unipolar major or minor depressive disorder
  • Hamilton Depression Rating Scale score of at least 18
  • Depression that is associated with cerebrovascular disease
  • Failed at least 1 treatment for vascular depression

Location and Contact Information

Stephanie Rosazza, RA III      319-353-5807

      University of Iowa Health Care, Iowa City,  Iowa,  52242-1087,  United States; Recruiting
Stephanie Rosazza, RA III  319-353-5807 
Robert G Robinson, MD,  Principal Investigator
Ricardo E Jorge, MD,  Principal Investigator

More Information

Study ID Numbers:  63405-01A1
Record last reviewed:  September 2004
Last Updated:  October 13, 2004
Record first received:  September 4, 2002 Identifier:  NCT00044798
Health Authority: United States: Federal Government processed this record on 2005-04-08

Cache Date: April 9, 2005